Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a planned Q2 launch. Learn more on SUPN stock here.

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, ... Inquired about Qelbree’s Q1 pricing dynamics and the infrastructure for ONAPGO’s patient access.

Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease. Supernus on Tuesday said the FDA green light makes Onapgo ...

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit exceeding Wall Street’s expectations. ... Stacy Ku (TD Cowen): Inquired ...

ONAPGO™ (apomorphine hydrochloride) ... Supernus will host a conference call and webcast today, May 6, 2025, at 4:30 p.m. Eastern Time to discuss these results.

Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal ... the U.S. Food and Drug Administration approved Supernus' drug-device combination, Onapgo, ...

Supernus will make ONAPGO available in the second quarter of 2025. Price Action: SUPN stock is down 14.10% at $34.20 at the last check on Wednesday. Read Next: ...

--Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced today that the ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...